Immutep Quarterly Activities Report Q4 FY25
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build...
Year: 2025
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in...
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment DeviceMARIETTA, Ga., July 30,...
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Valitor Highlights Three-fold Increase with VLTR-559 in Sustained Potency and Durability over Aflibercept in Preclinical Ocular Wet AMD Models
-Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit...
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease...
Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy
BERKELEY, Calif, July 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital...
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital...
Paragon Genomics and Genecast Announce Global Partnership to Advance Precision Oncology
Leaders in pioneering cancer diagnostics and NGS target enrichment technologies join forces to accelerate access to advanced molecular diagnostics for...
Bionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, Belgium
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) recently participated in the European Cytogenomics Conference,...
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients...
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8,...
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology...
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT)...
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the...
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing,...
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
Conference Call to be Held Monday, August 4, 2025, at 8:30 am ETNEW YORK, July 30, 2025 (GLOBE NEWSWIRE) --...
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD,...
PetVivo Holdings Inc. to Trade on OTCQX Best Market
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned...